Disease · MONDO_0003220
gallbladder carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. gallbladder carcinoma. Diseases, record MONDO_0003220. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003220
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Gall bladder carcinoma (adeno), Gall bladder carcinoma (adenocarcinoma), cancer of gallbladder, cancer of the gallbladder, carcinoma gallbladder, carcinoma of gall bladder, carcinoma of gallbladder, carcinoma of the gallbladder, gall bladder carcinoma
- Open Targets
Drugs40
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| LEUCOVORIN | CHEMBL1679 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| EPIRUBICIN | CHEMBL417 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SOMATOSTATIN | CHEMBL1823872 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 40
See all 40 drugsTargets67
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 6 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| TYMS | Thymidylate synthase | 5 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 3 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 3 | Stem cell growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 3 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 2 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 2 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
1 to 10 of 67
See all 67 targetsTrials32
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | Phase 3 | 452 | 2024-10-22 | Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma | CISPLATIN, GEMCITABINE HYDROCHLORIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00789958 | S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct | Phase 2 | 105 | 2016-09-22 | Extrahepatic Bile Duct Cancer, Gallbladder Cancer | CAPECITABINE, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00338988 | Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma | Phase 2 | 44 | 2010-12-08 | Cancer of the Gallbladder, Cancer of the Biliary Tract | CAPECITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | Phase 2 | 40 | 2014-01-29 | Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Undifferentiated Gallbladder Carcinoma, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma | ERLOTINIB, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT03779035 | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection | Phase 3 | 460 | Cholangiocarcinoma, Gall Bladder Carcinoma | CAPECITABINE, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | Phase 2/3 | 300 | Biliary Tract Cancer, Cholangiocarcinoma | CISPLATIN, GEMCITABINE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT04969887 | Combination Immunotherapy in Rare Cancers Under InvesTigation | Phase 2 | 240 | Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01053390 | New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma | Phase 3 | 216 | Gallbladder Neoplasms | CISPLATIN, EPIRUBICIN, FLUOROURACIL, LEUCOVORIN, SOMATOSTATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06662877 | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment | Phase 2/3 | 206 | Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor | CATEQUENTINIB, PACLITAXEL, TEGAFUR | Its record names the disease | ClinicalTrials.gov | |
| NCT01926236 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers | Phase 3 | 162 | Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer | FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 32
See all 32 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: deaths from any cause | 237 of 294 | 115 of 147 | 441 | NCT03768414 | Trial comparisons |
| Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: serious adverse events | 27 of 287 | 11 of 134 | 421 | NCT03768414 | Trial comparisons |
| Stratum: 1 Prior Regimen vs Stratum 2: No Prior Therapy: serious adverse events | 4 of 18 | 2 of 26 | 44 | NCT00338988 | Trial comparisons |
Papers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003220
GET https://conductscience.org/api/diseases/v1/MONDO_0003220/drugs?page=2